Last update 26 Dec 2024
Targeting GPC3 Chimeric Antigen Receptor Autologous T Cell (OriCell Therapeutics)
Last update 26 Dec 2024
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms Anti-GPC3 CAR T-cell therapy (OriginCell), G3-CAR-Ori2, gpc3-car-ori2 + [3] |
Target |
Mechanism GPC3 modulators(Glypican-3 modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Targeting GPC3 Chimeric Antigen Receptor Autologous T Cell (OriCell Therapeutics)A Phase Ib/II, Open-Label, Multi-Center Study to Investigate the Safety, PK, and Efficacy of Ori-C101 in Advanced Hepatocellular Carcinoma (HCC) Patients (BEACON)
一项在既往接受过至少二线规范系统性治疗后失败或不可耐受的GPC3阳性晚期肝细胞癌（HCC）受试者中评估靶向GPC3嵌合抗原受体自体T细胞注射液（Ori-C101）的安全性、药代动力学和初步疗效的Ⅰb/Ⅱ期开放性、多中心临床研究
[Translation] A Phase Ib/II open-label, multicenter clinical study to evaluate the safety, pharmacokinetics, and preliminary efficacy of GPC3-targeted chimeric antigen receptor autologous T cell injection (Ori-C101) in subjects with GPC3-positive advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to at least two lines of standard systemic therapy
A Phase I study of Glypican-3(GPC3) Peptide Vaccine for Pediatric Patients with Refractory Tumors - GPC3 Vaccine PI for Pediatric Tumors
100 Clinical Results associated with Targeting GPC3 Chimeric Antigen Receptor Autologous T Cell (OriCell Therapeutics)
Login to view more data
100 Translational Medicine associated with Targeting GPC3 Chimeric Antigen Receptor Autologous T Cell (OriCell Therapeutics)
Login to view more data
100 Patents (Medical) associated with Targeting GPC3 Chimeric Antigen Receptor Autologous T Cell (OriCell Therapeutics)
Login to view more data
100 Deals associated with Targeting GPC3 Chimeric Antigen Receptor Autologous T Cell (OriCell Therapeutics)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Hepatocellular Carcinoma | Phase 2 | CN | 15 Dec 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free